Question · asked by 1 review

HALOPERIDOL vs first‐generation antipsychotics: Leaving the study early ‐ short term ‐ due to lack of efficacy

It is very uncertain whether haloperidol changes leaving the study early due to inefficacy of treatment as a measure… compared with first‐generation antipsychotics (very low certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Haloperidol vs first‐generation antipsychotics
Leaving the study early due to inefficacy of treatment as a measure of overall efficacy (short term) · people with schizophrenia
It is very uncertain whether haloperidol changes leaving the study early due to inefficacy of treatment as a measure… compared with first‐generation antipsychotics (very low certainty).
Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic… (2015) · Cochrane Headline outcomes only
RR 0.93 [0.4, 2.16]13 studies · 507 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders
2015 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.